TrialBlood advances2022

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.

Laurie H Sehn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.